Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
HER2-Positive Locally Advanced/Metastatic Breast Cancer Treatment Study
The main purpose of this study is to see whether MM-302 plus an anticancer drug called trastuzumab is more effective than other anticancer drugs (gemcitabine, capecitabine, or vinorelbine). The study will also see whether subjects taking MM-302 plus trastuzumab live longer, have fewer symptoms related to their cancer, experience a better quality of life, and have fewer side effects than subjects receiving other anticancer drugs.
In order to participate you must meet the following criteria:
- Have histologically or cytologically confirmed invasive cancer of the breast.
- Have documented locally advanced/ metastatic disease which is not amenable to resection with curative intent.
- Have been previously treated with trastuzumab in any setting.
- Have progressed on or be intolerant to both pertuzumab and ado-trastuzumab in the locally advanced or metastatic setting.
You will be excluded from the study if any of the following criteria apply to you:
- Have previously been treated with doxorubicin, liposomal doxorubicin, epirubicin, mitoxantrone, or any other anthracycline derivative.
- Have central nervous system (CNS) metastases, unless you have been treated and are stable without symptoms for 4 weeks after completion of treatment and must be off steroids for at least 4 weeks prior to enrollment.
This is a partial list of inclusion and exclusion criteria.